Skip to main content

Table 4 Summary of P. aeruginosa isolates from SMART (N = 1200) NS to IMI/RELa,b

From: In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

MICc (μg/mL) N Class A Class B Class C
PER GES VEB Other ESBL KPC Any MBL AmpC onlyd
4 313 12 (4%) 9 (3%) 18 (6%) 8 (3%) 3 (1%) 9 (3%) 254 (81%)
8 239 4 (2%) 49 (21%) 7 (3%) 3 (1%) 5 (2%) 29 (12%) 142 (59%)
16 128 37 (29%) 1 (1%) 3 (2%) 9 (7%) 31 (24%) 47 (37%)
32 84 26 (31%) 6 (7%) 36 (43%) 16 (19%)
64 404 12 (3%) 1 (< 1%) 9 (2%) 370 (92%) 12 (3%)
128 14 14 (100%)
> 128 18 17 (94%) 1 (6%)
Total number of isolates 16 133 27 14 32 506 472
  1. ESBL extended-spectrum β-lactamase, IMI/REL imipenem/relebactam, KPC Klebsiella pneumoniae carbapenemase, MBL metallo-β-lactamase, MIC minimum inhibitory concentration, NS non-susceptible
  2. aClass D enzymes were not detected in any of the isolates collected
  3. bIncludes SMART 2009, 2011, 2015, and 2016 data. Approximately 100 isolates possessed more than one acquired β-lactamase. For purposes of this table, each of these isolates was only counted once; the specific category each isolate was assigned to was based on the following algorithm: MBL > KPC > GES > other ESBL
  4. cImipenem minimum inhibitory concentration in the presence of 4 μg/mL of relebactam
  5. dIsolates that only encoded AmpC, and not any of the other studied β-lactamases. All 472 isolates contained a gene for chromosomal PDC and 2 isolates also that contained a gene for a plasmid-borne AmpC (ie, FOX-14 and DHA-1); both of these isolates had an imipenem/relebactam MIC of 8 μg/mL